¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"end product inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • end
    ³¡, Á¾¸», ¸»´Ü
  • end apparatus
    Á¾¸»ÀåÄ¡
  • end artery
    ³¡µ¿¸Æ
  • end group
    ¸»´Ü±â
  • end organ
    Á¾¸»±â°ü
  • end organ deafness
    Á¾¸»±â°ü³­Ã»
  • end-brush
    Ãà»è³¡°¡Áö
  • end-bud
    ²¿¸®½Ï
  • end-diastolic
    È®À帻±â
  • end-diastolic pressure
    È®Àå±â¸»¾Ð·Â
  • end-diastolic volume
    È®Àå±â¸»¿ëÀû
  • end-foot
    Á¾¸»´ÜÃß
  • end-pressure
    Á¾¾Ð, Á¾¸»¾Ð
  • end-systolic volume
    ¼öÃà±â¸»¿ëÀû
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • substitution product
    ġȯü
  • acromial end
    ºÀ¿ì¸®³¡
  • apical end
    ²ÀÁö³¡
  • end apparatus
    Á¾¸»ÀåÄ¡
  • end artery
    ³¡µ¿¸Æ
  • end to side anastomosis
    ³¡¿·¿¬°á(¼ú), ´ÜÃø¿¬°á(¼ú)
  • Krause¡¯s end bulb
    Å©¶ó¿ìÁ¦³¡¸Á¿ï
  • double-end graft
    ¾ç³¡À̽Ä, ½Ö´ÜÀ̽Ä
  • end-organ deafness
    Á¾¸»±â°ü³­Ã»
  • free end saddle partial denture
    À¯¸®´Ü±¹ºÎÀÇÄ¡
  • end
    ³¡
  • end-brush
    Ãà»è³¡°¡Áö
  • end-bud
    ²¿¸®½Ï
  • end-foot
    (¢¡bouton terminal) Á¾¸»´ÜÃß
  • end-pressure
    Á¾¾Ð, Á¾¸»¾Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • Internal inhibition
    ³»ºÎ¾ïÁ¦(Үݻåäð¤)
  • Lateral inhibition
    ÃøºÎ¾ïÁ¦(ö°Ý»åäð¤)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ionic product
    ÀÌ¿ÂÀû(¡­îÝ), À̿»깰.
  • metabolic product
    ´ë»ç»ê¹°(¡­ß§Úª).
  • otoacoustic emission, distortion product
    ÀÌÀ½Çâ¹æ»ç¿Ö°î¹°
  • product costing
    Á¦Ç°°¡°Ý»êÁ¤
  • product of metabolism
    ´ë»ç»ê¹°(ÓÛÞóß§Úª).
  • skin care product
    ÇǺΰü¸®Á¦
  • split product
    ºÐ¸®»ê¹°.
  • substitution product
    ġȯü(öÇüµô÷).
  • tensile product
    ½ÅÀåÀû(ãßíåîÝ).
  • acromial end
    ºÀ¿ì¸®³¡
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • end apparatus
    Á¾¸»ÀåÄ¡(ðûØÇíûöÇ).
  • end artery
    Á¾µ¿¸Æ(ðûÔÑØæ).
  • end bulb of Krause
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cohesive end ligation
    Á¡ÂøÁ¾´Ü°áÂû(ïÄó·ðûӮ̿óÎ)
  • dead-end complex
    Á¾¸»º¹ÇÕü(ðûØÇÜÜùêô÷)
  • end absorption
    ³¡ÆÄÀå(÷îíþ) Èí¼ö(ýåâ¥)
  • end carbon chain
    ³¡Åº¼Ò(÷©áÈ) »ç½½
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • end labeling
    Á¾´ÜÇ¥Áö (ðûÓ®øöò½)
  • end plate
    Á¾¸»ÆÇ(ðûØÇ÷ù)
  • end point
    Á¾¸»Á¡(ðûØÇïÇ)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • fast-assembly end
    ?
  • frayed end
    Ç®¸° ³¡
  • minus end
    ¸¶À̳ʽº Á¾´Ü(ðýÓ¨)
  • plus end
    Ç÷¯½º Á¾´Ü(ðûÓ®)
  • reducing end
    ȯ¿ø¼º Á¾´Ü(ü½êªàõðûÓ®)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EP echo planar; ectopic pregnancy; edible portion; electrophoresis; electrophysiologic; electroprecipit...
EIC elastase inhibition capacity; enzyme inhibition complex
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
CEEA curved end-to-end anastomosis [stapler]
EDCS end-diastolic chamber stiffness; end-diastolic circumferential stress
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DPE Distortion Product Emission
DPOE Distortion product otoacoustic emissions
DPE Distortion-product otoacoustic emission
DAP Dose area product
ESP Excretory-secretory product
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central end
    Á᫐ ¸»´Ü
  • end apparatus
    Á¾¸» ÀåÄ¡
  • end feel
    Á¾¸»°¨, Á¾¸» °¨°¢
  • end path
    Á¾·Î
  • end-expiration
    È£Èí °áÇ٠ȣ±â ¸»±â
  • end-feel
    Á¾¸»°¨
    ¿ÏÀüÇÑ ´Éµ¿ °³±¸·ÎºÎÅÍ ¿ÏÀüÇÑ ¼öµ¿ °³±¸±îÁö °üÀýÀ» ¼ÕÀ¸·Î Á¶ÀÛÇÏ´Â µ¿¾È ´À²¸Áö´Â ÀúÇ×°¨.
  • end-organ
    Á¾¸» ±â°ü, ¸»´Ü±â, Á¾¸» ½Å°æ ¼Òü
    Áö°¢ ½Å°æÀÇ ÇÇÆ÷µÈ Ä¿´Ù¶õ Á¾¸»ºÎ.
  • free end saddle partial denture
    À¯¸®´Ü ±¹ºÎ ÀÇÄ¡
    ¾Ç±ÃÀÇ ÈĹ濡 ÀÜÁ¸Ä¡°¡ ÆíÃø ¶Ç´Â ¾çÃø¼ºÀ¸·Î ¾øÀ» ¶§ Á¦ÀÛµÈ ±¹¼Ò ÀÇÄ¡ÀÌ´Ù.
  • joint end-feel
    °üÀý Á¾¸»°¨
  • left ventricular end-diastolic volume
    Á ½É½Ç À̿ϱ⸻ ¿ëÀû
  • soft end feel
    ºÎµå·¯¿î Á¾¸»°¨
  • vibrating end
    Áøµ¿ ¸»´ÜºÎ
  • zero end expiratory pressure
    È£±â¸» ¹«¾Ð, È£±â¸» ¹«¿µ¾Ð
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
product packaging Form in which product is processed or wrapped and labelled.
(12 Dec 1998)
product recovery The process of separating a desired recombinant protein from the growth medium and the other elements in the host cells in which it was grown.
(14 Nov 1997)
product surveillance, postmarketing Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
(12 Dec 1998)
secondary product <plant biology> End product of plant cell metabolism, which accumulates in or is secreted from, the cell. Includes anthocyanins, alkaloids, etc. Some are of major economic importance, for example as drugs. In contrast to a primary product that is involved in the vital metabolism of the plant.
(18 Nov 1997)
spallation product An atomic species produced in the course of the spallation of any atom.
(05 Mar 2000)
substitution product A product obtained by replacing one atom or group in a molecule with another atom or group.
(05 Mar 2000)
double product The product of systolic blood pressure multiplied by the heart frequency; a measure of heart work load.
See: Robinson index.
(05 Mar 2000)
trade name product <pharmacology> Trademarked proprietary preparations containing the generic substance. Some foreign trade name products have been selectively included here due to the relative popularity of the generic medication.
(17 Mar 1998)
fission product An atomic species produced in the course of the fission of a larger atom such as 235U.
(05 Mar 2000)
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • parity product
    ÆÐ¸®Æ¼ Á¦Ç°
  • partial product
    ºÎºÐÀû
  • product
    »ý»êǰ;Á¦ÀÛ¹°;°á°ú;¼º°ú;°ö;Àû
  • product concept
    Á¦Ç° °³³ä(²÷ÀÓ¾øÀÌ Á¦Ç°ÀÇ °³¼±À» ²ÒÇÏ´Â °æ¿µ Áöħ)
  • product liability
    (ºÒ·® »óǰ¿¡ ´ëÇØ ¼ÒºñÀÚ¿¡°Ô Áö´Â) »ý»ê¹°(ÀÚ) Ã¥ÀÓ
  • product life cycle
    Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ
  • product line
    (¸¶ÄÉÆÃ)Á¦Ç° ¶óÀÎ(°°Àº ±â´ÉÀ» °¡Áø ¼­·Î °ü·Ã ±íÀº Á¦Ç°±º)
  • product mix
    (¸¶ÄÉÆÃ)Á¦Ç° ¹Í½º(ÆÇ¸ÅµÇ´Â ÀüÁ¦Ç°ÀÇ ¸®½ºÆ®,Æø°ú ±íÀÌÀÇ µÎÂ÷¿ø)
  • residual product
    ÀÜ¿© »ý»ê¹°;ºÎ»ê¹°
  • staple product
    ÁÖ¿ä »ê¹°
  • by-end
    À̱âÀûÀÎ µ¿±â
  • end
    ³¡,¸ñÀû,°á¸»
  • to the end
    ³¡±îÁö
  • END
    European Nuclear Disarmament
  • East End
    ·±´ø µ¿Á· ³¡(ÀÌÀüÀÇ ºó¹Î°¡)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á